ArticleBMC cancer2009
Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen.
Article in BMC cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Surface Complex V couples proton gradient across the plasma membrane to ATP production in cancer.Research square · 2026Article
- Surface Complex V couples proton gradient across the plasma membrane to ATP production in cancer.bioRxiv : the preprint server for biology · 2026Article
- Multi-omic data integration and exploiting metabolic models using systems biology approach increase precision in subtyping and early diagnosis of cancer.Quantitative biology (Beijing, China) · 2025Article
- Spatial and temporal dynamics of ATP synthase from mitochondria toward the cell surface.Communications biology · 2023Article
- The Flavone Cirsiliol fromCells · 2022Article
- The function of Cav-1 in MDA-MB-231 breast cancer cell migration and invasion induced by ectopic ATP5B.Medical oncology (Northwood, London, England) · 2021Article
- Comparative Proteomic Study Shows the Expression of Hint-1 in Pituitary Adenomas.Diagnostics (Basel, Switzerland) · 2021Article
- Proteomic Characterization of Two Extracellular Vesicle Subtypes Isolated from Human Glioblastoma Stem Cell Secretome by Sequential Centrifugal Ultrafiltration.Biomedicines · 2021Article
- Integrated Analyses Reveal the Multi-Omics and Prognostic Characteristics of ATP5B in Breast Cancer.Frontiers in genetics · 2021Article
- Natural products and other inhibitors of FEuropean journal of medicinal chemistry · 2020Review
- A novel RNA aptamer identifies plasma membrane ATP synthase beta subunit as an early marker and therapeutic target in aggressive cancer.Breast cancer research and treatment · 2019Article
- Ubiquinol-cytochrome C reductase core protein II promotes tumorigenesis by facilitating p53 degradation.EBioMedicine · 2019Article
- Identification of LEA, a podocalyxin-like glycoprotein, as a predictor for the progression of colorectal cancer.Cancer medicine · 2018Article
- A molecular signature of lung cancer: potential biomarkers for adenocarcinoma and squamous cell carcinoma.Oncotarget · 2017Article
- Possible Involvement of F1F0-ATP synthase and Intracellular ATP in Keratinocyte Differentiation in normal skin and skin lesions.Scientific reports · 2017Article
- Metastasized lung cancer suppression by Morinda citrifolia (Noni) leaf compared to Erlotinib via anti-inflammatory, endogenous antioxidant responses and apoptotic gene activation.Molecular and cellular biochemistry · 2016Article
- Metabolism-related enzyme alterations identified by proteomic analysis in human renal cell carcinoma.OncoTargets and therapy · 2016Article
- Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells.American journal of cancer research · 2015Article
- Inhibition of the ecto-beta subunit of F1F0-ATPase inhibits proliferation and induces apoptosis in acute myeloid leukemia cell lines.Journal of experimental & clinical cancer research : CR · 2012Article
- Inhibition of tumor cell surface ATP synthesis by pigment epithelium-derived factor: implications for antitumor activity.International journal of oncology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntibody-based immunotherapy has achieved some success for cancer. But the main problem is that only a few tumor-associated antigens or therapeutic targets have been known to us so far. It is essential to identify more immunogenic antigens (especially cellular membrane markers) for tumor diagnosis and therapy.
methodsThe membrane proteins of lung adenocarcinoma cell line A549 were used to immunize the BALB/c mice. A monoclonal antibody 4E7 (McAb4E7) was produced with hybridoma technique. MTT cell proliferation assay was carried out to evaluate the inhibitory effect of McAb4E7 on A549 cells. Flow cytometric assay, immunohistochemistry, western blot and proteomic technologies based on 2-DE and mass spectrometry were employed to detect and identify the corresponding antigen of McAb4E7.
resultsThe monoclonal antibody 4E7 (McAb4E7) specific against A549 cells was produced, which exhibited inhibitory effect on the proliferation of A549 cells. By the proteomic technologies, we identified that ATP synthase beta subunit (ATPB) was the corresponding antigen of McAb4E7. Then, flow cytometric analysis demonstrated the localization of the targeting antigen of McAb4E7 was on the A549 cells surface. Furthermore, immunohistochemistry showed that the antigen of McAb4E7 mainly aberrantly expressed in tumor cellular membrane in non-small cell lung cancer (NSCLC), but not in small cell lung cancer (SCLC). The rate of ectopic expressed ATPB in the cellular membrane in lung adenocarcinoma, squamous carcinoma and their adjacent nontumourous lung tissues was 71.88%, 66.67% and 25.81% respectively.
conclusionIn the present study, we identified that the ectopic ATPB in tumor cellular membrane was the non-small cell lung cancer (NSCLC) associated antigen. ATPB may be a potential biomarker and therapeutic target for the immunotherapy of NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.